Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Nucleos(t)ide Analogue (NA)

Phase 1

AAusper Biopharma Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Hepatitis B InfectionRecruiting

Chronic Hepatitis B InfectionPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Chronic Hepatitis B Infection

NCT07511218

Clinical

Trials by Indication[1]

Chronic Hepatitis B Infection1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AHB - 171 Injection in Healthy Participants (HP) and Chronic Hepatitis B(CHB) Participants

Recruiting·AAusper Biopharma Co., Ltd.·Phase 1·NCT07511218·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nucleos(t)ide Analogue (NA). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nucleos(t)ide Analogue (NA). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ausper Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAusper Biopharma Co., Ltd.

Related News